Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort
Journal of Affective Disorders. 2019-02-01; 245: 468-474
DOI: 10.1016/j.jad.2018.11.004
Lire sur PubMed
1. J Affect Disord. 2019 Feb 15;245:468-474. doi: 10.1016/j.jad.2018.11.004. Epub
2018 Nov 6.
Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine
approach of the national FACE-SZ cohort.
Fond G(1), Godin O(2), Schürhoff F(3), Berna F(4), Aouizerate B(5), Capdevielle
D(6), Chereau I(7), D’Amato T(8), Dubertret C(9), Dubreucq J(10), Faget C(11),
Leignier S(10), Lançon C(11), Mallet J(9), Marulaz L(3), Misdrahi D(12),
Passerieux C(13), Rey R(8), Schandrin A(6), Urbach M(13), Vidailhet P(14),
Leboyer M(3); FACE-SZ (FondaMental Academic Centers of Expertise for
Schizophrenia) group; Boyer L(11), Llorca PM(7).
Author information:
(1)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, EA 3279: CEReSS -Centre d’Etude et de Recherche sur
les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille
13005, France. Electronic address: .
(2)Fondation FondaMental, Créteil, France; Sorbonne Universités, UPMC Univ Paris
06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique,
F-75013, Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis
d’Epidémiologie et de Santé Publique, F-75013, Paris, France.
(3)Fondation FondaMental, Créteil, France; INSERM U955, équipe de psychiatrie
translationnelle, Créteil, France; Université Paris-Est Créteil, DHU Pe-PSY,
Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil, France.
(4)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(5)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; INRA, NutriNeuro, University
of Bordeaux, U1286 F-33076, Bordeaux, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm 1061, Montpellier, France.
(7)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003, Clermont-Ferrand Cedex 1, France.
(8)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre de
Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Equipe
PSYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678,
Bron Cedex, France.
(9)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot,
Sorbonne Paris Cité, Faculté de médecine, France.
(10)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(11)Fondation FondaMental, Créteil, France; Aix-Marseille Univ, Faculté de
Médecine – Secteur Timone, EA 3279: CEReSS -Centre d’Etude et de Recherche sur
les Services de Santé et la Qualité de vie, 27 Boulevard Jean Moulin, Marseille
13005, France.
(12)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux F-33076, France; CNRS UMR 5287-INCIA France.
(13)Fondation FondaMental, Créteil, France; Centre Hospitalier de Versailles,
Service de psychiatrie et d’addictologie adulte, Le Chesnay, EA 4047 HANDIReSP,
UFR des Sciences de la Santé Simone Veil, Université Versailles
Saint-Quentin-en-Yvelines, Versailles, France.
(14)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
BACKGROUND: Major Depressive Disorder (MDD) is a therapeutic challenge in
schizophrenia (SZ). Untangling different forms of MDD appears as the best
current strategy to improve remission to treatment in the so-called precision
medicine approach.
AIMS: The objectives of the present study were to determine (i) the prevalence
of Inflammatory Depression (ID) in stabilized SZ outpatients (ii) if ID was
associated with clinical or cognitive profiles that may help clinicians
detecting ID (iii) if antidepressants were effective in ID and (iv) the
biological correlates of ID that may orientate personalized treatments.
METHOD: Participants were consecutively included and received a thorough 2 days-
clinical assessment.
RESULTS: 785 subjects were recruited in the FACE-SZ cohort. 289 (36.8%) were
diagnosed with MDD (remitted or unremitted), of them 57 with ID (19.7%). No
clinical or cognitive features were associated with ID (all p > 0.05). ID has
been associated with increased abdominal perimeter (aOR = 4.48, p = 0.002) and
latent Toxoplasma infection (aOR = 2.19, p = 0.04). While antidepressants were
associated with decreased depressive symptoms level in ID, 44% of the subjects
remained unremitted under antidepressant, with no association with CRP blood
levels.
CONCLUSIONS: ID may not differ from other forms of depression by its clinical
symptoms but by its aetiologies. ID is associated with increased perivisceral
fat and latent Toxoplasma infection that are both potentially related to
gut/microbiota disturbances. Specific anti-inflammatory drugs and
microbiota-targeted therapeutics appear as promising strategies in the treatment
of inflammatory depression in schizophrenia.
Copyright © 2018 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.jad.2018.11.004
PMID: 30428447 [Indexed for MEDLINE]